<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265016</url>
  </required_header>
  <id_info>
    <org_study_id>RBC in CAD</org_study_id>
    <secondary_id>13-037</secondary_id>
    <nct_id>NCT02265016</nct_id>
  </id_info>
  <brief_title>Regulation and Signaling of Red Blood Cell (RBC) Endothelial Nitric Oxide Synthase (eNOS) in Patients With Stable and Unstable Coronary Artery Disease</brief_title>
  <official_title>Regulation and Signaling of RBC-eNOS in Patients With Stable and Unstable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is measurement of expression and activity of RBC eNOS in different&#xD;
      clinical cohorts of patients with coronary artery disease and acute coronary syndrome and to&#xD;
      investigate the importance of the NO-stimulated reaction cascade in terms of sGC and PKG.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of red cell endothelial nitric oxide-synthase (eNOS)-expression and - activity</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deformability and stability of red blood cell membrane</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>by Laser assisted Optical Rotational Cell Analyzer (LORCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular function</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>Determination of microvascular function with Laser-Doppler Perfusion Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral and central hemodynamic measurement</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of arterial stiffness</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>Determination of arterial stiffness with pulse wave analysis during blood pressure measurement or echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of flow-mediated dilation</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of nitrate and nitrite in blood plasma and red blood cells (RBC)</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of nitric oxide and cyclic guanosine monophosphate (cGMP) in blood plasma and in red blood cells</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of endothelial microparticles</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aging and turnover of red blood cells</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Redox status of red blood cells</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>Determination of redox status of red blood cells will be measured on free thiole with thioltracker and reactive oxygen species( ROS) by dihydrodichlorofluorescein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggregation of red blood cells</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>Determination of aggregation of red blood cells with LORCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregometry</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression and function of soluble guanylyl cyclase (sGC) in red blood cells</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>measurement of enzyme expression and activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression and activity of Protein Kinase G (PKG)</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>measurement of enzyme expression and activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of leucocyte populations and leucocyte function</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>flow-cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of tetrahydrobiopterin-metabolism</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Endothelial NO-synthase</condition>
  <arm_group>
    <arm_group_label>Patients with CAD</arm_group_label>
    <description>Patients with stable coronary artery disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with ACS</arm_group_label>
    <description>Patients with acute coronar syndrome, instable Angina pectoris and low-risk NSTEMI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control group</arm_group_label>
    <description>healthy control group without clinical apparent arteriosclerosis</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        3 groups:&#xD;
&#xD;
          -  ACS group (100 Patients)&#xD;
&#xD;
          -  stable CAD group (100 Patients)&#xD;
&#xD;
          -  healthy control group (100 Healthy Volunteers)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  for ACS(acute coronary syndrome)-Group: angiographic coronary artery disease; acute&#xD;
             coronary syndrome, defined by EITHER unstable angina pectoris with significant&#xD;
             coronary stenosis (troponin negative, without significant ST-elevation) OR low-risk&#xD;
             NSTEMI (Troponin positive, without significant ST-elevation)&#xD;
&#xD;
          -  for stable CAD-Group: angiographic coronary artery disease; no acute coronary syndrome&#xD;
             within the last 3 months&#xD;
&#xD;
          -  healthy control group: No clinical or angiographical signs of apparent atherosclerosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acute inflammation (CRP &gt; 1 mg/dl, leukocyte &gt; 11.000/Âµl)&#xD;
&#xD;
          -  malignant diseases&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  medication with NO-donors ( e.g.isosorbide mononitrate, isosorbide dinitrate, glyceryl&#xD;
             trinitrate, Molsidomin, Ranexa)&#xD;
&#xD;
          -  patients with STEMI or high-risk NSTEMI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malte Kelm, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Pneumology and Angiology, University Hospital Duesseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik fÃ¼r Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Principle Investigator Prof. Dr. Malte Kelm</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>angina pectoris</keyword>
  <keyword>non-ST-segment elevation myocardial infarction</keyword>
  <keyword>red blood cells</keyword>
  <keyword>erythrocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

